Usefulness of bevacizumab in colon cancer patients
Pichon Riviere A, Augustovski F, Ferrante D, Regueiro A, Garcia Marti S, Glujovsky D
Record ID 32005000659
The aim of this study was to assess the usefulness of bevacizumab in treating colon cancer patients
Authors' results and conclusions: During the last years, new drugs have been approved for the treatment of advanced-stage colon cancer treatment. Two of them are traditional cytotoxic drugs (irinotecan and oxaliplatin) and there are two other ones - monoclonal antibodies against molecular components (bevacizumab and cetuximab). The addition of both irinotecan and oxaliplatin to the standard plan (5FU-leucovorin) achieves a higher efficacy by doubling the response rate in these patients from 20 to 40% and increasing the average survival from 11 to 20 months.
Authors' recomendations: This report analyzes the main clinical trial which studied the effects of bevacizumab in colon cancer patients. This study included 813 patients with advanced-stage colon cancer with no previous chemotherapy where one group received 5FU leucovorin irinotecan (IFL) plus bevacizumab and the other group received IFL plus placebo. There was an increase in the bevacizumab group survival of 5 months (15.6 vs. 20.3 months). This study promoted its approval by the Food and Drug Administration (FDA) and its coverage by some health organizations in this country.
Authors' methods: Overview
Project Status: Completed
URL for project: http://www.iecs.org.ar/
Year Published: 2004
English language abstract: An English language summary is available
Publication Type: Not Assigned
- Chemotherapy, Adjuvant
- Drug Administration Schedule
- Angiogenesis Inhibitors
- Antibodies, Monoclonal
- Antineoplastic Combined Chemotherapy Protocols
- Colorectal Neoplasms
Organisation Name: Institute for Clinical Effectiveness and Health Policy
Contact Address: Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name: email@example.com
Contact Email: firstname.lastname@example.org
Copyright: Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.